Negozia Regeneron Pharmaceuticals, Inc. - REGN CFD
Aggiungi a Preferiti- Riepilogo
- Dati Storici
- Eventi
- Conto Economico
- Stato Patrimoniale
- Cash Flow
- Titolarità
Spread | 1.22 | ||||||||
Commissione overnight su posizione lunga
Long position overnight fee
Vai alla piattaforma | -0.024068% | ||||||||
Commissione overnight su posizione corta
Short position overnight fee
Vai alla piattaforma | 0.001846% | ||||||||
Ora commissione overnight | 21:00 (UTC) | ||||||||
Quantità negoziata min | 1 | ||||||||
Valuta | USD | ||||||||
Margine | 20% | ||||||||
Borsa | United States of America | ||||||||
Commissioni per il trading | 0% |
*Information provided by Capital.com
Regeneron Pharmaceuticals Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Chiusura Preced.* | 801.72 |
Apertura* | 811.57 |
Variazione a 1 Anno* | 21.46% |
Range Giornaliero* | 805.24 - 823.29 |
Range a 52 sett. | 538.01-812.70 |
Volume Medio (10 giorni) | 723.97K |
Volume Medio (3 mesi) | 12.73M |
Capitalizzazione di Mercato | 87.70B |
Rapporto P/E | 20.98 |
Azioni Circolanti | 109.33M |
Ricavi | 12.17B |
EPS | 38.24 |
Dividendi (Rendimento %) | N/A |
Beta | 0.22 |
Prossima Data per Utili | May 2, 2023 |
Tutti i dati sono forniti da Refinitiv, ad eccezione dei dati contrassegnati da un asterisco, che sono *dati forniti da Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Chiusura | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 819.63 | 17.38 | 2.17% | 802.25 | 823.61 | 795.78 |
Mar 23, 2023 | 801.72 | -1.10 | -0.14% | 802.82 | 811.60 | 787.54 |
Mar 22, 2023 | 750.68 | -8.68 | -1.14% | 759.36 | 764.03 | 750.15 |
Mar 21, 2023 | 758.90 | 0.41 | 0.05% | 758.49 | 764.47 | 750.58 |
Mar 20, 2023 | 758.21 | 16.55 | 2.23% | 741.66 | 759.65 | 741.65 |
Mar 17, 2023 | 747.35 | 1.81 | 0.24% | 745.54 | 753.70 | 740.70 |
Mar 16, 2023 | 748.89 | -2.86 | -0.38% | 751.75 | 752.05 | 725.56 |
Mar 15, 2023 | 759.88 | 7.50 | 1.00% | 752.38 | 765.58 | 752.38 |
Mar 14, 2023 | 766.66 | 13.56 | 1.80% | 753.10 | 769.29 | 753.01 |
Mar 13, 2023 | 752.05 | 6.55 | 0.88% | 745.50 | 768.02 | 740.46 |
Mar 10, 2023 | 746.30 | 2.75 | 0.37% | 743.55 | 758.66 | 736.92 |
Mar 9, 2023 | 743.15 | -1.92 | -0.26% | 745.07 | 755.33 | 738.07 |
Mar 8, 2023 | 744.62 | -27.39 | -3.55% | 772.01 | 772.76 | 743.57 |
Mar 7, 2023 | 773.11 | -7.63 | -0.98% | 780.74 | 782.86 | 770.56 |
Mar 6, 2023 | 779.91 | 5.06 | 0.65% | 774.85 | 785.00 | 768.08 |
Mar 3, 2023 | 778.57 | 13.47 | 1.76% | 765.10 | 779.63 | 764.97 |
Mar 2, 2023 | 767.91 | -0.13 | -0.02% | 768.04 | 772.37 | 760.64 |
Mar 1, 2023 | 769.69 | 15.12 | 2.00% | 754.57 | 772.43 | 754.57 |
Feb 28, 2023 | 757.54 | 2.49 | 0.33% | 755.05 | 765.22 | 747.60 |
Feb 27, 2023 | 757.26 | 7.44 | 0.99% | 749.82 | 771.13 | 749.82 |
Regeneron Pharmaceuticals, Inc. Events
Ora (UTC) (UTC) | Paese | Evento |
---|---|---|
No events scheduled |
- Annuale
- Trimestrale
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ricavi totali | 16071.7 | 8497.1 | 7863.4 | 6710.8 | 5872.23 |
Ricavi | 16071.7 | 8497.1 | 7863.4 | 6710.8 | 5872.23 |
Costo dei Ricavi, Totale | 2437.5 | 1119.9 | 782.2 | 434.1 | 397.061 |
Profitto Lordo | 13634.2 | 7377.2 | 7081.2 | 6276.7 | 5475.17 |
Totale Costi Operativi | 7124.9 | 4920.5 | 5653.6 | 4176.4 | 3792.64 |
Costi Commerciali/Generali/Amministr., Totale | 1824.9 | 1346 | 1834.8 | 1556.2 | 1320.43 |
Ricerca e Sviluppo | 2908.1 | 2735 | 3036.6 | 2186.1 | 2075.14 |
Risultato d’Esercizio | 8946.8 | 3576.6 | 2209.8 | 2534.4 | 2079.59 |
Interessi Attivi (Oneri), Netti Non Operativi | 328.8 | 139.1 | 88.1 | 13.7 | -25.119 |
Altro, Netto | 50.2 | 94.7 | 131.2 | 5.4 | 24.039 |
Utile Netto al Lordo delle Imposte | 9325.8 | 3810.4 | 2429.1 | 2553.5 | 2078.51 |
Utile Netto al Netto delle Imposte | 8075.3 | 3513.2 | 2115.8 | 2376.4 | 1524.71 |
Utile Netto al Lordo di Extra Elementi | 8075.3 | 3513.2 | 2115.8 | 2376.4 | 1524.71 |
Utile Netto | 8075.3 | 3513.2 | 2115.8 | 2444.4 | 1198.51 |
Reddito a Disposizione di Azionisti Ordinari Esclusi Extra. Elementi | 8075.3 | 3513.2 | 2115.8 | 2376.4 | 1524.71 |
Reddito a Disposizione di Azionisti Ordinari Inclusi Extra. Elementi | 8075.3 | 3513.2 | 2115.8 | 2444.4 | 1198.51 |
Rettifica Diluizione | 0 | ||||
Utile Netto Diluito | 8075.3 | 3513.2 | 2115.8 | 2444.4 | 1198.51 |
Azioni Medie Ponderate Diluite | 112.2 | 115.1 | 114.6 | 114.8 | 115.954 |
EPS Diluito Esclusi Elementi Straordinari | 71.9724 | 30.523 | 18.4625 | 20.7003 | 13.1493 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
EPS Diluito Normalizzato | 71.9724 | 30.523 | 18.4625 | 20.7003 | 13.1493 |
Totale Elementi Straordinari | 68 | -326.2 | |||
Other Operating Expenses, Total | -45.6 | -280.4 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Ricavi totali | 2965.1 | 4951.7 | 3452.8 | 5138.5 | 2528.7 |
Ricavi | 2965.1 | 4951.7 | 3452.8 | 5138.5 | 2528.7 |
Costo dei Ricavi, Totale | 404.9 | 982.6 | 453.2 | 693.7 | 308 |
Profitto Lordo | 2560.2 | 3969.1 | 2999.6 | 4444.8 | 2220.7 |
Totale Costi Operativi | 1706.6 | 2312 | 1605.6 | 1791.3 | 1416 |
Costi Commerciali/Generali/Amministr., Totale | 450 | 559.6 | 445 | 414.7 | 405.6 |
Ricerca e Sviluppo | 843.8 | 785.6 | 665.4 | 714.2 | 742.9 |
Other Operating Expenses, Total | -20.2 | -15.8 | 42 | -31.3 | -40.5 |
Risultato d’Esercizio | 1258.5 | 2639.7 | 1847.2 | 3347.2 | 1112.7 |
Interessi Attivi (Oneri), Netti Non Operativi | -224.8 | -151.8 | -43.3 | 394.6 | 129.3 |
Altro, Netto | 27.4 | 15.5 | 12.7 | 11 | 11 |
Utile Netto al Lordo delle Imposte | 1061.1 | 2503.4 | 1816.6 | 3752.8 | 1253 |
Utile Netto al Netto delle Imposte | 973.5 | 2229 | 1632.2 | 3098.9 | 1115.2 |
Utile Netto al Lordo di Extra Elementi | 973.5 | 2229 | 1632.2 | 3098.9 | 1115.2 |
Utile Netto | 973.5 | 2229 | 1632.2 | 3098.9 | 1115.2 |
Reddito a Disposizione di Azionisti Ordinari Esclusi Extra. Elementi | 973.5 | 2229 | 1632.2 | 3098.9 | 1115.2 |
Reddito a Disposizione di Azionisti Ordinari Inclusi Extra. Elementi | 973.5 | 2229 | 1632.2 | 3098.9 | 1115.2 |
Utile Netto Diluito | 973.5 | 2229 | 1632.2 | 3098.9 | 1115.2 |
Azioni Medie Ponderate Diluite | 113.1 | 113.4 | 113.9 | 110.8 | 110.5 |
EPS Diluito Esclusi Elementi Straordinari | 8.60743 | 19.6561 | 14.3301 | 27.9684 | 10.0923 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
EPS Diluito Normalizzato | 8.85588 | 19.6561 | 14.3301 | 27.9684 | 10.0923 |
Spese Straordinarie (Utile) | 28.1 |
- Annuale
- Trimestrale
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Attivo Corrente | 14014.9 | 9779.1 | 7689.1 | 6447.6 | 4335.03 |
Disponibilità Liquide e Investimenti a Breve Termine | 5694.7 | 3587 | 3214.3 | 2809.9 | 1409.58 |
Disponibilità Liquide e Mezzi Equivalenti | 2885.6 | 2193.7 | 1617.8 | 1467.7 | 812.733 |
Investimenti a Breve Termine | 2809.1 | 1393.3 | 1596.5 | 1342.2 | 596.847 |
Totale Crediti, Netto | 6036.5 | 4114.7 | 2672.2 | 2243.2 | 1974.34 |
Accounts Receivable - Trade, Net | 6036.5 | 4114.7 | 2672.2 | 2243.2 | 1974.34 |
Total Inventory | 1502.8 | 1485.7 | 1014.6 | 822.3 | 513.878 |
Prepaid Expenses | 332.4 | 160.8 | 387.1 | 243.3 | 224.972 |
Other Current Assets, Total | 448.5 | 430.9 | 400.9 | 328.9 | 212.26 |
Total Assets | 25434.8 | 17163.3 | 14805.2 | 11734.5 | 8764.29 |
Property/Plant/Equipment, Total - Net | 3482.2 | 3221.6 | 2890.4 | 2575.8 | 2358.6 |
Property/Plant/Equipment, Total - Gross | 4880.3 | 4352.7 | 3812.8 | 3304.5 | 2924.9 |
Accumulated Depreciation, Total | -1398.1 | -1131.1 | -922.4 | -728.7 | -566.294 |
Long Term Investments | 6878 | 3194.8 | 3312.4 | 1800.5 | 1486.49 |
Other Long Term Assets, Total | 1059.7 | 967.8 | 913.3 | 910.6 | 584.157 |
Total Current Liabilities | 3932.5 | 2697.4 | 2096.6 | 1442.8 | 1135.48 |
Accounts Payable | 564 | 475.5 | 418.1 | 218.2 | 178.183 |
Accrued Expenses | 1880.5 | 1502.3 | 1037.4 | 751.3 | 636.668 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 719.7 | 0 | |||
Other Current Liabilities, Total | 768.3 | 719.6 | 641.1 | 473.3 | 320.632 |
Total Liabilities | 6666 | 6138 | 3715.5 | 2977.2 | 2620.21 |
Total Long Term Debt | 1980 | 2695.7 | 713.9 | 708.5 | 703.453 |
Capital Lease Obligations | 0 | 717.2 | 713.9 | 708.5 | 703.453 |
Other Liabilities, Total | 753.5 | 744.9 | 905 | 825.9 | 781.272 |
Total Equity | 18768.8 | 11025.3 | 11089.7 | 8757.3 | 6144.08 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.112 |
Additional Paid-In Capital | 8087.5 | 6716.2 | 4428.6 | 3911.6 | 3512.83 |
Retained Earnings (Accumulated Deficit) | 18968.3 | 10893 | 7379.8 | 5254.3 | 2946.73 |
Treasury Stock - Common | -8260.9 | -6613.3 | -739.9 | -396.4 | -316.24 |
Other Equity, Total | -26.2 | 29.3 | 21.1 | -12.3 | 0.64 |
Total Liabilities & Shareholders’ Equity | 25434.8 | 17163.3 | 14805.2 | 11734.5 | 8764.29 |
Total Common Shares Outstanding | 108.675 | 106.951 | 110.277 | 109.006 | 107.625 |
Long Term Debt | 1980 | 1978.5 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Attivo Corrente | 14306 | 14014.9 | 13775.4 | 13337.6 | 10055.1 |
Disponibilità Liquide e Investimenti a Breve Termine | 7050.6 | 5694.7 | 5787.6 | 3910.8 | 3503.8 |
Disponibilità Liquide e Mezzi Equivalenti | 3345.7 | 2885.6 | 3432.4 | 2072.2 | 1437.9 |
Investimenti a Breve Termine | 3704.9 | 2809.1 | 2355.2 | 1838.6 | 2065.9 |
Totale Crediti, Netto | 4839 | 6036.5 | 5452 | 6998.6 | 4173 |
Accounts Receivable - Trade, Net | 4839 | 6036.5 | 5452 | 6998.6 | 4173 |
Total Inventory | 1465.7 | 1502.8 | 1550.1 | 1448.9 | 1665.3 |
Prepaid Expenses | 424.9 | 332.4 | 482 | 444.3 | 213.6 |
Other Current Assets, Total | 525.8 | 448.5 | 503.7 | 535 | 499.4 |
Total Assets | 26348.7 | 25434.8 | 23671.5 | 21485.9 | 17772.2 |
Property/Plant/Equipment, Total - Net | 3556.4 | 3482.2 | 3395.7 | 3358.5 | 3262.6 |
Long Term Investments | 7130.7 | 6878 | 5671.3 | 3940.3 | 3583.7 |
Other Long Term Assets, Total | 1355.6 | 1059.7 | 829.1 | 849.5 | 870.8 |
Total Current Liabilities | 3007.6 | 3932.5 | 3714.8 | 3732.4 | 3217.8 |
Accounts Payable | 470.3 | 564 | 427 | 476 | 542.9 |
Accrued Expenses | 2046 | 2206.8 | 2061 | 2018 | 1492.2 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 719.7 | 719 | 718.4 | 717.8 |
Other Current Liabilities, Total | 491.3 | 442 | 507.8 | 520 | 464.9 |
Total Liabilities | 6434 | 6666 | 6413.5 | 6358.6 | 5795.2 |
Total Long Term Debt | 2700.4 | 1980 | 1979.6 | 1979.2 | 1978.9 |
Long Term Debt | 1980.4 | 1980 | 1979.6 | 1979.2 | 1978.9 |
Capital Lease Obligations | 720 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 726 | 753.5 | 719.1 | 647 | 598.5 |
Total Equity | 19914.7 | 18768.8 | 17258 | 15127.3 | 11977 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 8754.1 | 8087.5 | 7919.3 | 7225.8 | 6887.8 |
Retained Earnings (Accumulated Deficit) | 19941.8 | 18968.3 | 16739.3 | 15107.1 | 12008.2 |
Treasury Stock - Common | -8611.2 | -8260.9 | -7410.2 | -7221.4 | -6935.3 |
Other Equity, Total | -170.1 | -26.2 | 9.5 | 15.7 | 16.2 |
Total Liabilities & Shareholders’ Equity | 26348.7 | 25434.8 | 23671.5 | 21485.9 | 17772.2 |
Total Common Shares Outstanding | 109.507 | 108.675 | 108.527 | 106.72 | 106.644 |
- Annuale
- Trimestrale
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Reddito Netto/Linea di Partenza | 8075.3 | 3513.2 | 2115.8 | 2444.4 | 1198.51 |
Liquidità da Attività Operative | 7081.3 | 2618.1 | 2430 | 2195.1 | 1307.11 |
Liquidità da Attività Operative | 286.2 | 235.9 | 210.3 | 148.2 | 145.467 |
Deferred Taxes | -147.1 | 75.6 | -130.6 | -140 | 318.809 |
Elementi Non Monetari | 783.4 | 297 | 435 | 439.5 | 570.858 |
Cash Taxes Paid | 1218.4 | 188.1 | 342.3 | 205.6 | 754.843 |
Interessi di Cassa Corrisposti | 55.8 | 23.2 | 25 | 22.3 | 18.678 |
Variazioni del Capitale Circolante | -1916.5 | -1503.6 | -200.5 | -697 | -926.533 |
Liquidità da Attività di Investimento | -5384.7 | -70.6 | -2027.8 | -1463 | -1005.18 |
Spese in Conto Capitale | -551.9 | -614.6 | -429.6 | -383.1 | -272.626 |
Altri Elementi del Cash Flow da Investimenti, Totale | -4832.8 | 544 | -1598.2 | -1079.9 | -732.556 |
Liquidità da Attività di Finanziamento | -1005.8 | -1970.5 | -252.1 | -77.1 | -24.4 |
Elementi del Cash Flow da Finanziamenti | -1032.7 | -680.8 | -188 | -187.2 | -301.688 |
Emissione (Dismissione) di Azioni, Netto | 26.9 | -3271.6 | -64.1 | 110.1 | 240.213 |
Emissione (Dismissione) di Debiti, Netto | 0 | 1981.9 | 0 | 37.075 | |
Variazione Netta della Liquidità | 690.8 | 577 | 150.1 | 655 | 277.53 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 973.5 | 8075.3 | 5846.3 | 4214.1 | 1115.2 |
Cash From Operating Activities | 2101.7 | 7081.3 | 4708.8 | 1295.2 | 668.5 |
Cash From Operating Activities | 74.3 | 286.2 | 211.7 | 138.5 | 67.4 |
Deferred Taxes | -225 | -147.1 | 58.8 | 51.8 | 10.1 |
Non-Cash Items | 455.7 | 783.4 | 153.1 | -84.9 | 15.2 |
Changes in Working Capital | 823.2 | -1916.5 | -1561.1 | -3024.3 | -539.4 |
Cash From Investing Activities | -1705.3 | -5384.7 | -3372 | -933.2 | -1059 |
Capital Expenditures | -141.8 | -551.9 | -397 | -263.8 | -115.3 |
Other Investing Cash Flow Items, Total | -1563.5 | -4832.8 | -2975 | -669.4 | -943.7 |
Cash From Financing Activities | 64.7 | -1005.8 | -99.2 | -484.6 | -366.4 |
Financing Cash Flow Items | -98.8 | -1032.7 | -450.3 | -180.7 | -154.5 |
Issuance (Retirement) of Stock, Net | 163.5 | 26.9 | 351.1 | -303.9 | -211.9 |
Net Change in Cash | 461.1 | 690.8 | 1237.6 | -122.6 | -756.9 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 |
Nome investitore | Tipo investitore | Percentuale in circolazione | Azioni detenute | Variazione azioni | Data partecipazioni | Rating di turnover |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 9.914 | 10658247 | 268103 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.0656 | 8671077 | 74457 | 2022-12-31 | LOW |
Capital World Investors | Investment Advisor | 5.8065 | 6242435 | 16836 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.7272 | 6157131 | -211997 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.6145 | 4960885 | -90874 | 2022-12-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 4.4213 | 4753254 | 301869 | 2022-12-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2475 | 2416247 | -27042 | 2022-12-31 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 2.0678 | 2223059 | -63450 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0538 | 2207990 | -32123 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.4723 | 1582798 | -28736 | 2022-12-31 | LOW |
Capital International Investors | Investment Advisor | 1.4231 | 1529943 | -237193 | 2022-12-31 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.2962 | 1393537 | 7205 | 2023-02-28 | LOW |
Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 1.2443 | 1337681 | -378936 | 2022-12-31 | LOW |
Yancopoulos (George D) | Individual Investor | 1.1527 | 1239194 | -79973 | 2022-04-12 | LOW |
Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0395 | 1117533 | 13700 | 2022-12-31 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.025 | 1102002 | -76069 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.899 | 966467 | 1776 | 2022-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.7992 | 859202 | -22201 | 2022-12-31 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7733 | 831369 | -41616 | 2022-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7213 | 775449 | -12042 | 2022-12-31 | LOW |
Perché scegliere Capital.com? I nostri numeri parlano da soli.
Capital.com Group500K+
Traders
92K+
Clienti attivi mensilmente
$53M+
Volume di investimento mensile
$30M+
Prelevati mensilmente
Calcolatrice di trading
Calcola il tuo P&L ipotetico qualora avessi aperto un'operazione in CFD in una data specifica (seleziona una data) e l'avessi chiusa in una data diversa (seleziona una data).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
Su Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. è un'azienda biofarmaceutica che scopre, inventa, sviluppa, produce e commercializza medicine per il trattamento di disturbi medici gravi. La Società commercializza medicine per malattie degli occhi, alto colesterolo LDL (high-density lipoprotein) e disturbi infiammatori, e ha altri prodotti candidati in fase di sviluppo in altrre aree, tra cui artrite reumatoide, asma, dermatite atopica, dolore, cancro e malattie infettive. Tra i prodotti in commercio troviamo EYLEA (aflibercept) Iniezione, Praluent (alirocumab) Iniezione, ARCALYST (rilonacept) Iniezione per uso subcutaneo, Kevzara (sarilumab) Soluzione per iniezione subcutanea e ZALTRAP (ziv-aflibercept) Iniezione per infusione intravenosa. Al 31 dicembre 2016 la Società aveva 16 prodotti candidati in fase di sviluppo clinico: un programma clinico con trappola chimica e 15 prodotti per anticorpi monoclonali completamente umani.
- IndustriaBiotechnology / Medical Research
- Indirizzo777 Old Saw Mill River Rd, TARRYTOWN, NY, United States (USA)
- Dipendenti10368
- CEOP. Roy Vagelos
Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
10591
Conto Economico
- Annual
- Quarterly
Altri utenti guardano anche
Sei ancora alla ricerca di un broker di cui ti puoi fidare?
Unisciti agli oltre 500.000+ trader in tutto il mondo che hanno scelto di fare trading con Capital.com